DeepL Logo

Learn how DeepL delivered 345% ROI for global businesses

A commissioned Total Economic Impact™ study conducted by Forrester Consulting on behalf of DeepL showed that businesses achieved €2.79M in efficiency savings.

Illustration of DeepL's TEI report

Highlights of DeepL's TEI study

345%

return on investment

90%

less time spent on translation when using DeepL

€2.79 million

in efficiency savings over three years of use

50%

reduction in translation workload and productivity recapture

Preview of DeepL's TEI report

What's inside?

Investing in the right tools is a crucial decision for your business. To shed some light on how DeepL affects the bottom line, we commissioned Forrester Consulting to interview multinational organizations about the impact of DeepL's technology on their business. 

The numbers speak for themselves: AI translation saved the composite organization valuable time and resources and showed a positive return on investment.

The customers interviewed were headquartered in the US and Europe and expanding or operating internationally, with 1,600-40,000 employees and revenues ranging from €365M to €33.7B. 

For over 20 years, Forrester's Total Economic Impact™ (TEI) study has been the gold standard for evaluating the cost, benefits, flexibility, and risk of an investment. 

Download the report to learn more about DeepL’s business impact and how it helped the composite organization improve time-consuming translation processes, boost productivity, and improve customer experience.

“We really do save time resolving complaints with DeepL, which translates into cost reduction or profit realization. Because there is no time spent [manually trying to understand the complaint], we can now spend time on more diverse, value-added work and be more productive.” 

Software applications lead, energy company

“I think that we knew that opening into new markets meant that we had to be able to translate quickly — and that our caseload would probably explode on us.”

Director of Cyber Technologies, pharmaceutical company